FindTrial
Sign In

Sospension of androgen hormonal deprivation in patients with high levels of CgA - CgA

Sospension of androgen hormonal deprivation in patients with high levels of CgA - CgA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-011257-40-IT
Enrollment
Unknown
Registered
2009-05-12
Start date
2009-06-05
Completion date
Unknown
Last updated
2014-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer histologic diagnosis of prostatic carcinoma in hormonal escape MedDRA version: 9.1 Level: HLT Classification code 10018187 Term: Genitourinary neoplasms malignancy and gender unspecified

Interventions

Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Triptorelin Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 11

Sponsors

AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: - Cancer histologic diagnosis of prostatic carcinoma - hormanonal escape Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - lack chronic opf renal efficiency - other diagnosis of cancer pathologies

Design outcomes

Primary

MeasureTime frame
Main Objective: Valutation of changes of plasmatic CgA in patients with prostatic cancer;Secondary Objective: To compare levels of CgA in the two groups of patients: the first takes LHRH-A and the other that does`t take LHRH-A;Primary end point(s): To evaluate levels of CgA in the two groups of patients—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026